Fun Route: New Discovery of 4531-54-8

From this literature《Development of a HPLC-DAD stability-indicating method and compatibility study of azathioprine and folic acid as a prerequisite for a monolayer fixed-dose combination》,we know some information about this compound(4531-54-8)Recommanded Product: 1-Methyl-4-nitro-1H-imidazol-5-amine, but this is not all information, there are many literatures related to this compound(4531-54-8).

So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic.Brusac, Edvin; Jelicic, Mario-Livio; Amidzic Klaric, Daniela; Nigovic, Biljana; Keser, Sabina; Mornar, Ana researched the compound: 1-Methyl-4-nitro-1H-imidazol-5-amine( cas:4531-54-8 ).Recommanded Product: 1-Methyl-4-nitro-1H-imidazol-5-amine.They published the article 《Development of a HPLC-DAD stability-indicating method and compatibility study of azathioprine and folic acid as a prerequisite for a monolayer fixed-dose combination》 about this compound( cas:4531-54-8 ) in Analytical Methods. Keywords: HPLC stability compatibility azathioprine folic acid monolayer dose combination. We’ll tell you more about this compound (cas:4531-54-8).

Adherence in chronic diseases is a major problem which can be combated by prescribing fixed-dose combinations in the therapy of the disease. Thus, a combination of azathioprine and folic acid in the treatment of inflammatory bowel disease is highly required, but prior to formulation development, chem. compatibility of the two drugs needs to be investigated. In this work, differential scanning calorimetry, isothermal stress testing, in vitro dissolution and forced degradation studies were utilized to investigate compatibility. Moreover, a stability-indicating HPLC-DAD method for the determination of parent drugs and five of their impurities was developed, validated and applied to the inhouse sample. Compatibility testing revealed no noteworthy interactions of the two drug substances. Furthermore, forced degradation showed no substantial differences between the degradation profiles of each active pharmaceutical ingredient, their mixture and the inhouse sample, further reinforcing the claim of compatibility. Lastly, the inhouse sample was analyzed: it was shown to conform to the requirements of relevant regulatory documents for all the investigated analytes, demonstrating the method’s viability for use in formulation and process development. Our results give way to the possibility of realization of said fixed-dose combination.

From this literature《Development of a HPLC-DAD stability-indicating method and compatibility study of azathioprine and folic acid as a prerequisite for a monolayer fixed-dose combination》,we know some information about this compound(4531-54-8)Recommanded Product: 1-Methyl-4-nitro-1H-imidazol-5-amine, but this is not all information, there are many literatures related to this compound(4531-54-8).

Reference:
Thiomorpholine – Wikipedia,
Thiomorpholine | C4H9NS – PubChem